Fig. 3.

Comparisons of the clinical outcomes between patients in the low- and high-MIF-level groups. (A) ROC curve for evaluating the ability of serum MIF levels to predict the therapeutic outcomes of the neoadjuvant therapy. AUC, area under the curve; TPR, true positive rate; FPR, false positive rate. (B) Percentages of patients that had different clinical responses in the low-MIF-level group (n = 43) and the high-MIF-level group (n = 7). PR, partial response; SD, stable disease; PD, progression of the disease. Kaplan–Meier (C) DFS and (D) OS curves of patients in the low- and high-MIF-level groups. *p < 0.05, **p < 0.01, ***p < 0.001.